References
- Leer J A. Efficacy of a betamethasone dipropionate topical glycol preparation in the management of severe psoriasis. Clin Ther 1980; 3: 156–67
- Kansky A. The effects of increased penetration of betamethasone dipropionate in a propylene glycol base (Diprolene) for psoriasis. J Int Med Res 1981; 9: 128–31
- Downie D A, Swarbrick P T, Salmon R M. The effect of betamethasone dipropionate glycol ointment 0.05% (Diprosone O.V.) on adrenocortical function. Aust J Dermatol 1981; 22: 113–18
- Aldana Gutierrez G. Efficacy and tolerance of betamethasone dipropionate propylene glycol for resistant psoriasis and other resistant steroid-responsive dermatoses. J Int Med Res 1981; 9: 448–52
- Gip L, Hamfelt A. A double-blind clinical trial of Diprolene ointment versus dermovate ointment for resistant psoriasis and atopic dermatitis. Curr Ther Res 1981; 30: 895–904
- Gip L, Hamfelt A. A new propylene-glycol-based topical preparation of betamethasone dipropionate: double-blind evaluation of efficacy, safety and absorption. Acta Ther 1982; 8: 51–62
- Mauracher E, Blum G, Kropfli P, et al. Betamethasone dipropionate glycol ointment versus clobetasol propionate ointment. A multicentre trial in patients with resistant psoriasis and atopic dermatitis. Acta Ther 1983; 9: 197–207
- Gip L, Hamfelt A. Studies on the efficacy and adrenal effects of Diprolene ointment 0.05 percent and Dermovate ointment 0.05 percent in patients with psoriasis or other resistant dermatoses. Cutis 1984; 33: 215–24
- Jacobson C, Cornell R C, Savin R C. A comparison of Clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis. Cutis 1986; 37: 213–20
- Katz H I, Hien N T, Prawer S E, et al. Superpotent topical steroid treatment of psoriasis vulgaris - clinical efficacy and adverse function. J Am Acad Dermatol 1987; 16: 804–11
- Katz H I, Hien N T, Prawer S E, et al. Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987; 123: 1308–11
- Novak E, Francom S F, Schlagel C A. Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects. Clin Ther 1983; 6: 59–71
- Cornell R C, Stoughton R B. Correlation of the vasocon-striction assay and clinical activity in psoriasis. Arch Dermatol 1985; 121: 63–7
- Grizzle J E, Starmer C F, Koch G G. Analysis of categorical data by linear model. Biometrics 1969; 24: 489–504
- Chuang T Y, Samson C R. 0.05 percent betamethasone dipropionate in optimized cream vehicle for psoriasis. Cutis 1989; 43: 178–82